Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca's Coronavirus Vaccine Candidate Posts Positive Results

By Cory Renauer – Updated Jul 20, 2020 at 2:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The viral-vector based vaccine that AstraZeneca licensed from Oxford takes the lead.

Highly anticipated trial results for a coronavirus vaccine candidate AstraZeneca (AZN 0.41%) licensed from Oxford University reached The Lancet, a major medical journal, on Monday. And they put the adenovirus-based candidate, called AZD1222, firmly in the lead in the race to develop vaccines that can end the COVID-19 pandemic.  

This was a big early-stage trial with 1,077 healthy patients randomized to receive a single injection of AZD1222 or a meningitis vaccine as a control. The investigators also gave 10 patients in the AZD1222 group a booster shot after 28 days. 

A blood vial with a

Image source: Getty Images.

In terms of safety, the results fell somewhere between pretty good and wonderful. There weren't any serious adverse events related to AZD1222, but some patients did report injection-site pain and symptoms that could be mistaken for an actual COVID-19 infection. More than 20% of patients who were given AZD1222 reported moderate fever and fatigue.

It's too early to measure the number of COVID-19 infections in each group to gauge AZD1222's efficacy, but signs of an immune response that might stop SARS-CoV-2, the virus that causes COVID-19, were encouraging. Antibodies that glom onto the spike protein that SARS-CoV-2 uses to enter host cells reached peak production 28 days after injection and remained at high levels during a 56-day evaluation.

Oxford and AstraZeneca have already begun larger phase 3 clinical trials in Brazil, the U.K., and South Africa. A similar U.S. study to measure how many people injected with AZD1222 get COVID-19 compared with those given a placebo should begin shortly.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$53.24 (0.41%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.